Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 Myeloma Highlights
30 June 2026 | Virtual Meeting
Post-EHA 2026 Multiple Myeloma Highlights
Featuring presentations & discussions on selected Myeloma abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Karthik Ramasamy | Moderators: Cyrille Touzeau & Nisha Joseph
The Post-EHA 2026 Multiple Myeloma Highlights has been supported by CellCentric (Silver Sponsor). Supporters have no influence over the production of content.
Session 1: Latest in targeted immune modulation and cellular therapy
Arlocabtagene autoleucel, A GPRC5D-targeted CAR T-cell therapy for patients with relapsed/refractory multiple myeloma: Updated Phase 1 safety and efficacy results in patients with 1–3 prior regimens
Susan Bal University of Alabama, Birmingham, AL, United States
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, for patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE Phase 1 trial)
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Safety and efficacy of iberdomide-based quadruplet for patients with newly diagnosed multiple myeloma: The IDEAL Phase I/II trial results
Prashant Kapoor Mayo Clinic Rochester, Rochester, MN, United States
Updated results of a phase 1 first-in-human study of cemsidomide, a novel MONODAC® degrader, with dexamethasone (DEX) in patients with RRMM
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Panel Discussion
Session 2: Advances in T-cell engager monotherapy in smoldering myeloma & amyloidosis
Phase 3 randomized trial of anselamimab demonstrates improvement in all-cause mortality in Κ light-chain amyloidosis
Ashutosh Wechalekar University College London, London, United Kingdom
Initial efficacy and safety data from the Phase 1/2 LINKER-AL2 study of linvoseltamab (linvo) monotherapy in patients with relapsed or refractory (RR) systemic light chain (AL) amyloidosis
Ashutosh Wechalekar University College London, London, United Kingdom
Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the Phase 2 ERASMM (EMN34) study
Claudio Cerchione Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Teclistamab improves depth of response and PFS versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: results from the Phase 2 ImmunoPRISM trial
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Panel Discussion
Session 3: Recent progess in T-cell engager combination approaches in NDMM and RRMM
Teclistamab (tec) +/- lenalidomide (len) versus len alone as maintenance therapy post-transplant in newly diagnosed multiple myeloma (NDMM): Updated safety run-in (sri) results from EMN30/MAJESTEC-4
Niels van de Donk VU University Medical Center, Amsterdam, Netherlands
High MRD negativity rates and prolonged PFS with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone in transplant ineligible newly-diagnosed myeloma: Results of the BELA-DRD study
Evangelos Terpos University of Athens, Athens, Greece
Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs dara plus pom and dexamethasone (DPD) in relapsed/refractory multiple myeloma (RRMM): MONUMENTAL-3
Meral Beksac Istinye University Ankara Liv Hospital, Turkey
MAJESTEC-9: A Phase 3 study of teclistamab monotherapy vs pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone (PVD/KD) in patients (PTS) with relapsed refractory multiple myeloma (RRMM)
Roberto Mina Winship Cancer Institute of Emory University, Atlanta, GA, United States
Teclistamab plus daratumumab (TEC-DARA) in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Analysis of MAJESTEC-3 based on cytogenetic and functional risk
Rahul Banerjee Fred Hutchinson Cancer Center, Seattle, WA, United States
Panel Discussion
